Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS).

"Conflicts of interest The authors declare that they have no competing interests."

"The TKK cohort study is designed, managed and analysed by iOMEDICO and has received continuous financial support from Merck Pharma GmbH/Merck Serono GmbH and temporary financial support from Amgen GmbH, Bayer AG, medac GmbH, Onkovis GmbH, Pfizer GmbH, Roche AG. None of the funders had any role in study design, data collection and analysis, interpretation of results, decision to publish or preparation of the manuscript. The authors thank all patients, physicians and study teams participating in the study. The authors also thank Dr Holger Hartmann (iOMEDICO) for support during conception of the cohort study, Dr Karin Potthoff (iOMEDICO) for critical review of the manuscript, Dr Judith Müller (iOMEDICO) and Dr Stephanie Dille (iOMEDICO) for support in preparation of the manuscript. The TKK is conducted in collaboration with the ‘Arbeitskreis Klinische Studien in onkologischen und hämatologischen Praxen e.V.’ and the ‘Arbeitsgemeinschaft Internistische Onkologie in der deutschen Krebsgesellschaft e.V.’"

"The Tumour Registry Colorectal Cancer (TKK) is an ongoing, prospective, multicentre, longitudinal, nationwide cohort study which started in 2006. Since then, 269 medical oncologists from all over Germany have recruited more than 6000 patients. This study was reviewed by an ethics committee and is registered at ClinicalTrial.gov (NCT00910819). Eligible patients are aged 18 or over with histologically confirmed colorectal cancer and systemic chemo‐ or targeted therapy (e.g. antibodies). Written informed consent was obtained from all patients. The TKK has previously been described in detail . Patients are treated according to physician choice and are followed for a minimum of 3 years (or until death, loss to follow‐up or withdrawal of consent)."